Lentiviral gene tranfer to porcine airway epithelia
Lentiviral gene tranfer to porcine airway epithelia
批准号:
7741445
负责人:
PAUL B MCCRAY
金额:
$28.86万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2014-06-30
关键词:
AllelesAnimal ModelAnimalsApicalBaculovirusesBindingBronchoscopyCellsCloningCodeComplementary DNACystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDefectDiseaseDisease ProgressionElectrolytesEngineeringEpitheliumExocrine pancreatic insufficiencyFamilyFamily suidaeFeline Immunodeficiency VirusGene DeliveryGene ExpressionGene TransferGenesGoalsHealthHumanIleusImmune responseInfectionInflammationInstructionKineticsKnock-in MouseLentivirus VectorLibrariesLifeLiquid substanceLiverLungLung diseasesMeasuresMeconiumModelingMorbidity - disease rateMutagenesisNasal EpitheliumNoseOrganOutcome MeasurePhenotypePneumoniaPoint MutationPropertyProteinsPulmonary Cystic FibrosisRelative (related person)ReporterResolutionScreening procedureSerial PassageSomatic CellSpecificitySubfamily lentivirinaeSurfaceSystemTestingTracheal EpitheliumTropismVesicular stomatitis Indiana virusViralVirusX-Ray Computed Tomographyairway epitheliumbasecell typecellular transductionclinical applicationdeltaF508-CFTR proteindirected evolutiongene therapyimprovedin vivomortalitymutantnovelpositional cloningpreventprogenitorprogramsreceptor bindingrespiratorystemtransduction efficiencyvectorvirus envelope
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Cystic fibrosis lung disease might be corrected by delivering a normal copy of the CFTR cDNA to
sufficient epithelia to restore electrolyte and liquid transport. Towards this goal, our Project has developed
lentiviral vectors based on feline immunodeficiency virus (FIV) because of their ability to integrate and
persist. We also identified a number of virus envelopes ("pseudotypes") that confer apical entry on
polarized epithelia. The testing of the utility of gene transfer for CF has been hindered by lack of an
animal model that recapitulates the human phenotype. Recently, this PPG developed a pig CF model.
Animals heterozygous for a CFTR null or AF508 knock in allele were generated. Remarkably, live born
CFTR'' and CFTR^^''^^ piglets share many features of human babies with CF including pancreatic
insufficiency, meconium ileus, liver involvement, and respiratory abnormalities. We will use this animal
model to evaluate the efficacy of lentiviral gene transfer in modifying CF pulmonary disease. There are 3
aims. Aim 1. Which lentiviral pseudotype achieves the best apical targeting and persistent gene
transfer? We propose a thorough comparison of several candidate envelopes in pig and human cells to
select an optimal vector pseudotype. We hypothesize that one or more pseudotyped lentivirus will target
surface airway epithelia that express CFTR and possess progenitor capacity. Aim 2. Can we increase
the gene transfer efficiency of the GP64 envelope by directed evolution on airway epithelia? We
identified the baculovirus GP64 envelope as having very favorable properties for in vivo airway
transduction. We hypothesize that we can further improve lentiviral gene transfer efficiency and
specificity by directed evolution of GP64. We will use a reverse genetics system to engineer a replication
competent GP64 pseudotyped VSV and perform serial passage on primary pig and human airway
epithelia using wild type GP64 to evolve an ainway adapted envelope. In a complementary approach, the
GP64 receptor binding domain will be randomly modified by PCR mutagenesis, and this library of novel
lentivirus mutants screened on ainA/ay epithelia. These same directed evolution approaches can be
applied to other candidates that emerge from Aim 1. Aim 3. Will lentiviral gene delivery correct the
CFTR defect and prevent or slow lung disease progression? We will perform gene transfer to the pig
ainA/ays using our optimized vectors to identify the pseudotypes with efficient gene transfer and
persistence. We hypothesize that FIV gene transfer of CFTR to the ainA/ays of cFTR'^^¿^''^''^¿^ pigs will
Drevent or significantly slow lung disease progression. Outcome measures will include in vivo bioelectrics,
ligh resolution CT scans, screening for infection and inflammation by bronchoscopy, and other measures
of lung health.
RELEVANCE (See instructions);
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Iowa StARR Scholars Program
-
批准号:10565958
-
项目类别:
-
资助金额:$32.24万
-
财政年份:2021
-
负责人:PAUL B MCCRAY
-
依托单位:
Iowa StARR Scholars Program
-
批准号:10318208
-
项目类别:
-
资助金额:$32.24万
-
财政年份:2021
-
负责人:PAUL B MCCRAY
-
依托单位:
Molecular Therapies for Cystic Fibrosis Lung Disease
-
批准号:10470331
-
项目类别:
-
资助金额:$231.16万
-
财政年份:2020
-
负责人:PAUL B MCCRAY
-
依托单位:
Molecular Therapies for Cystic Fibrosis Lung Disease
-
批准号:10677580
-
项目类别:
-
资助金额:$231.16万
-
财政年份:2020
-
负责人:PAUL B MCCRAY
-
依托单位:
Administration Core
-
批准号:10677581
-
项目类别:
-
资助金额:$5.41万
-
财政年份:2020
-
负责人:PAUL B MCCRAY
-
依托单位:
Gene Editing Strategies to Correct CFTR Mutations
-
批准号:10024666
-
项目类别:
-
资助金额:$46.84万
-
财政年份:2020
-
负责人:PAUL B MCCRAY
-
依托单位:
Administration Core
-
批准号:10470332
-
项目类别:
-
资助金额:$5.41万
-
财政年份:2020
-
负责人:PAUL B MCCRAY
-
依托单位:
Gene Editing Strategies to Correct CFTR Mutations
-
批准号:10677600
-
项目类别:
-
资助金额:$44.11万
-
财政年份:2020
-
负责人:PAUL B MCCRAY
-
依托单位:
Molecular Therapies for Cystic Fibrosis Lung Disease
-
批准号:10024661
-
项目类别:
-
资助金额:$236.34万
-
财政年份:2020
-
负责人:PAUL B MCCRAY
-
依托单位:
Administration Core
-
批准号:10024662
-
项目类别:
-
资助金额:$5.41万
-
财政年份:2020
-
负责人:PAUL B MCCRAY
-
依托单位:
Administration Core
-
批准号:10248524
-
项目类别:
-
资助金额:$5.41万
-
财政年份:2020
-
负责人:PAUL B MCCRAY
-
依托单位:
Molecular Therapies for Cystic Fibrosis Lung Disease
-
批准号:10248523
-
项目类别:
-
资助金额:$232.02万
-
财政年份:2020
-
负责人:PAUL B MCCRAY
-
依托单位:
Gene Editing Strategies to Correct CFTR Mutations
-
批准号:10470336
-
项目类别:
-
资助金额:$44.11万
-
财政年份:2020
-
负责人:PAUL B MCCRAY
-
依托单位:
Gene Editing Strategies to Correct CFTR Mutations
-
批准号:10248528
-
项目类别:
-
资助金额:$44.11万
-
财政年份:2020
-
负责人:PAUL B MCCRAY
-
依托单位:
SCGE Disease Models Studies Supplement: Repair of a CFTR Nonsense Mutation Using Adenine Base Editing
-
批准号:10619058
-
项目类别:
-
资助金额:$49.09万
-
财政年份:2018
-
负责人:PAUL B MCCRAY
-
依托单位:
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
-
批准号:10274831
-
项目类别:
-
资助金额:$91.74万
-
财政年份:2018
-
负责人:PAUL B MCCRAY
-
依托单位:
Vector Core
-
批准号:8851185
-
项目类别:
-
资助金额:$15.08万
-
财政年份:2014
-
负责人:PAUL B MCCRAY
-
依托单位:
Mining a microRNA Regulated Gene Network to Rescue CFTR-DeltaF508 Function
-
批准号:9211383
-
项目类别:
-
资助金额:$41.57万
-
财政年份:2014
-
负责人:PAUL B MCCRAY
-
依托单位:
Mining a microRNA Regulated Gene Network to Rescue CFTR-DeltaF508 Function
-
批准号:9034662
-
项目类别:
-
资助金额:$47.93万
-
财政年份:2014
-
负责人:PAUL B MCCRAY
-
依托单位:
Epitope targeted AAVS for improved airway delivery
-
批准号:8522226
-
项目类别:
-
资助金额:$17.97万
-
财政年份:2012
-
负责人:PAUL B MCCRAY
-
依托单位:
海外基金